Recipharm, a Jordro, Sweden-based contract development and manufacturing organization, and LIDDS, a pharmaceutical company based in Helsingborg, Sweden, have signed an exclusive collaboration agreement regarding scale-up of the production process and commercial manufacture of Liproca Depot, LIDDS’ treatment for prostate cancer.

The agreement will be an important component for the upcoming Phase IIb study which is planned to start in 2016. In connection with the agreement, Recipharm is investing SEK 5 million ($587,730) in a private placement, thus becoming the third largest shareholder of LIDDS.

Source: Recipharm